DUROLANE Hyaluronic acid Single Injection Syringe

DUROLANE hyaluronic acid 1 pre-filled syringe x 3ml x 2 = TWICE or you get two products for a lower price!

Indication:

• symptomatic treatment of mild to moderate osteoarthritis
• degeneration of the knee or hip joint
• knee strengthening for athletes, skiers, seniors

Description:

DUROLANE contains hyaluronic acid of non-animal origin, produced by biosynthesis, which has been purified and stabilized. Hyaluronic acid injections into the joints restore the stickiness and elasticity of the sebaceous fluid , which can reduce pain and increase joint mobility. The preparation is intended for injection care in the symptomatic treatment of mild to moderate osteoarthritis and for the treatment of pain after arthroscopic procedures . It is not recommended for use by people with hypersensitivity to the components of the product. Symptomatic treatment associated with the treatment of mild to moderate pain caused by osteoarthritis of the ankles, elbows, wrists and fingers and toes. The product is also indicated for the treatment of pain caused by arthroscopic procedures in the presence of osteoarthritis for three months after the procedure. The preparation is supplied in a single-dose package - one injection. It can be applied only once during the entire treatment cycle. The recommended dose for knee, hip and shoulder joints is 3ml. He recommends a dose of 1-2 ml for medium-sized joints (e.g. elbow, ankle joint) and approx. 1 ml for small joints (e.g. thumb joint).

Ingredients:

• 1 ml of the product contains: sodium hyaluronate 20.0 mg,
• sodium chloride 9 mg,
• sodium hydrogen phosphate 0.14 mg,
• sodium dihydrogen phosphate monohydrate 0.03 mg,
• water for injection qs 1 ml

Packaging:

• 1 x pre-filled syringe of 3 ml
• 1 x pre-filled syringe of 3 ml

TWO PACKS FOR A LOWER AUCTION OFFER!

The preparation should be administered by an authorized physician.

The preparation should be administered by injection with strict adherence to aseptic technique.

The product has not been tested on pregnant women, breastfeeding women and children.

The product should only be administered into the joint cavity.

The preparation must not be administered intravenously and extra-articularly, into the synovial membrane and into the joint bag.

The preparation cannot be sterilized again, as this may cause it to decompose.

The preparation should be used with increased caution in patients with leg stagnation of venous or lymphatic origin.

Use a separate syringe with the preparation for each treated joint.

Due to the invasive nature of the injection, there is a low risk of infection.